The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1343
July 26, 2010
View Complete Issue         Table of Contents 2019 
A New Conjugate Meningococcal Vaccine (Menveo)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Conjugate Meningococcal Vaccine (Menveo)
July 26, 2010 (Issue: 1343)
The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Conjugate Meningococcal Vaccine (Menveo)
Article code: 1343b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.